Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resolaris in LGMD2B and FSHD
NCT02579239Phase 2Completed
- Sponsor
- aTyr Pharma
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 3
01
Overview
A Phase 2 trial of Resolaris in limb-girdle muscular dystrophy type 2B (LGMD2B), facioscapulohumeral muscular dystrophy (FSHD), sponsored by aTyr Pharma. Started Nov 2015; status: completed.
02
Drugs
Resolaris
03
Conditions
limb-girdle muscular dystrophy type 2B (LGMD2B)facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT02579239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579239.